Table 1.
Studies reporting outcomes in patients treated with Cytoreductive surgery with or without HIPEC for Colorectal PM
| Ref no | Type of study | No of Patients | Peritoneal Metastases alone | Other distant Metastases | CC-0/CC-1 | HIPEC | Drug | 5 year Disease free survival | 3 year OS | 5 year OS | Median OS | P-Value | Survival in CC-0/CC-1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37 | Prospective | 125 | 41 | 84 | 24.8 % | - | - | - | - | 4.8 % | 12 M | - | 22 % |
| 38 | Retrospective | 153 | - | - | 31 | - | - | - | - | - | - | - | 36 % |
| 39 | Retrospective | 50 | 27 | 23 | - | - | - | - | 45.5 % | 29.64 % | 32.4 M | ||
| 40 | Prospective | 122 | 122 | 85.2 % | Yes | CDDP MMC OX |
25.8 % | 33.5 (3 year OS) | |||||
| 41 | Prospective Comparative |
48 (96) | 48 | - | 100 % | Yes | OX | - | - | 51 % | 62.7 M | <.05 | 51 % |
| 42 | Retrospective | 523 | 523 | 77 | 84 % | Yes (86 %) | MMC OX |
10 % | 41 % | 27 % | 30.1 M | 29 % | |
| 43 | Prospective Case Control |
67 | 67 | Not specified | - | Yes | MMC | 34.7 M | 0.001 | ||||
| 44 | Prospective RCT | 52 (105) | 52 | - | Yes | MMC | 22.3 M | 45 % |
RCT: Randomized controlled Trial; CDDP: Cisplatin; MMC: Mitomycin-C, OX: Oxaliplatin; OS: Overall Survival; M: Months